 | |
| Company type | Public |
|---|---|
| ISIN | US92556V1061 |
| Industry | |
| Predecessors | |
| Founded | November 16, 2020 |
| Headquarters | , U.S. |
Area served | Worldwide |
Key people |
|
| Products | |
| Revenue |  US$15.39 billion (2023) |
| US$766 million (2023) | |
| US$54.7 million (2023) | |
| Total assets | US$47.69 billion (2023) |
| Total equity | US$20.47 billion (2022) |
Number of employees | c. 38,000 (2023) |
| Subsidiaries |
|
| Website | viatris |
| Footnotes / references [1] | |
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.[2]
The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.[3][4]
Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue.[5]
- ^ "Viatris Inc. 2023 Form 10-K Annual Report". U.S. Securities and Exchange Commission. February 28, 2024.
- ^ Gough, Paul J. (November 16, 2020). "After nearly 60 years, Mylan makes way for Viatris". American City Business Journals.
- ^ "Viatris picked as new name for a merged Mylan/Upjohn". Pittsburgh Post-Gazette. November 12, 2019.
- ^ Blankenship, Kyle (November 12, 2019). "Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?". FiercePharma.
- ^ "Fortune: Viatris Company Profile, News, Rankings". Fortune.com. Fortune. Retrieved June 2, 2021.